Universität zu Köln

Pfaar, O., Lang, S., Pieper-Fuerst, U., Astvatsatourov, A., Gerich, F., Klimek, L., Kramer, M. F., Reydelet, Y., Shah-Hosseini, K. and Moesges, R. (2018). Ultra-short-course booster is effective in recurrent grass pollen-induced allergic rhinoconjunctivitis. Allergy, 73 (1). S. 187 - 196. HOBOKEN: WILEY. ISSN 1398-9995

Full text not available from this repository.

Abstract

BackgroundA relevant proportion of allergic rhinoconjunctivitis (ARC) patients experience recurrent symptoms after successfully completing allergen immunotherapy (AIT). This prospective, controlled, noninterventional study used internationally standardized instruments to determine the clinical effects of a preseasonal, ultra-short-course booster AIT on clinical outcome parameters. MethodsThis two-arm study included patients aged 12 years with recurrent grass pollen-induced seasonal AR who had completed a successful course of any grass pollen AIT at least 5 years before enrolment. Overall, 56 patients received one preseasonal short-course booster AIT using tyrosine-absorbed grass pollen allergoids containing the adjuvant monophosphoryl lipid A (MPL (R)); 51 control patients received symptomatic medication. The combined symptom and medication score (CSMS) was recorded in the (peak) grass pollen season. Furthermore, concomitant (antiallergic) medication use, the patients' state of health, Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) results and safety/tolerability of the treatment were assessed. ResultsThe CSMS in the peak grass pollen season was significantly lower in the booster AIT group (=38.4%, P<.01). Moreover, significantly more patients in this group used no concomitant antiallergic medication throughout the peak grass pollen season. Twice as many patients in the booster AIT group as in the control group reported having a better state of health than in the preceding season. MiniRQLQ results showed significant differences favouring the booster AIT. The booster AIT was generally well tolerated, with only two patients reporting mild, grade 1 systemic adverse events. ConclusionBooster AIT using tyrosine-absorbed allergoids containing the adjuvant MPL (R) effectively prevents re-occurrence of symptoms in patients with grass pollen-induced ARC.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Pfaar, O. UNSPECIFIED UNSPECIFIED UNSPECIFIED Lang, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Pieper-Fuerst, U. UNSPECIFIED UNSPECIFIED UNSPECIFIED Astvatsatourov, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Gerich, F. UNSPECIFIED UNSPECIFIED UNSPECIFIED Klimek, L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kramer, M. F. UNSPECIFIED UNSPECIFIED UNSPECIFIED Reydelet, Y. UNSPECIFIED UNSPECIFIED UNSPECIFIED Shah-Hosseini, K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Moesges, R. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-199973
DOI:	10.1111/all.13240
Journal or Publication Title:	Allergy
Volume:	73
Number:	1
Page Range:	S. 187 - 196
Date:	2018
Publisher:	WILEY
Place of Publication:	HOBOKEN
ISSN:	1398-9995
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language MONOPHOSPHORYL-LIPID-A; ADVERSE SYSTEMIC REACTIONS; SUBLINGUAL IMMUNOTHERAPY; SUBCUTANEOUS IMMUNOTHERAPY; REAL-LIFE; POLLINEX QUATTRO; EUROPEAN SURVEY; VACCINE; RHINITIS; EFFICACY Multiple languages Allergy; Immunology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/19997